Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Rivaroxaban vs Xarelto in Healthy Fed Males
NCT04729998Phase 1Unknown
- Sponsor
- Pharmtechnology
- Start
- Jan 2021
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve from time 0 to last measurable concentration at 48 hours. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04729998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729998.